SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built…
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United…
international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030,…
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer,…
Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY…
Quadria Capital, Asia’s premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target.…
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities…
Global pharmaceutical company Lupin Limited has announced a licensing and supply agreement with SteinCares, a prominent specialty healthcare firm in Latin America, for the commercialization of its biosimilar ranibizumab across…
(Headquarters: Tokyo; CEO: Haruo Naito) announced that its in-house developed dual orexin receptor antagonist, DAYVIGO® (brand name in China: 达卫可®, generic name: lemborexant), has been approved in China for the…
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sibeprenlimab, an investigational…
Empowering Patients Through Collaboration: Astellas’ Commitment to Pompe Disease Awareness This article shares real patient stories to raise awareness about Pompe disease. Individual experiences may differ. This content is for…
Running from Friday through June 3 at McCormick Place Convention Center, the 2025 ASCO Annual Meeting promises to unveil pivotal data from a wide range of clinical trials. Experts suggest…